News

First-bite syndrome: a novel complication of carotid body paraganglioma resection


 


Therapy options
Treatments for first-bite syndrome offer variable results. Treatment outcomes experienced by patients in the various studies focusing on first-bite and Horner’s syndromes are summarized in Table 2, with only a few therapies having reported positive effects. Concomitant amitriptyline (25 mg at bedtime) reduced the intensity as well as the duration of pain, as reported by Phillips and Farquhar-Smith.9 In the cases from Chiu et al,8 two of three patients with first-bite syndrome found slight pain relief following tympanic neurectomy. Another patient found that amitriptyline and carbamazepine reduced the pain to only the first few bites.9 Casserly et al1 reported on a patient with Horner’s syndrome and first-bite syndrome whose pain improved with pregabalin (Lyrica).

Perhaps the most promising treatment is botulinum toxin. In a study by Ali et al,5 a woman who received no benefit from multiple narcotics and surgeries received an injection of botulinum toxin into the side of the parotid gland, where the pain was most intense. Four months after undergoing tympanic neurectomy (to relieve the symptoms of four surgical resections including mandibular osteotomies and parapharyngeal-space dissection), the patient received an injection of 75 units of botulinum toxin diluted in 2 mL of saline solution into the right parotid gland. Less than 48 hours later, the patient reported that the pain was markedly improved.5 If untreated, the pain associated with first-bite syndrome goes; it has been reported to resolve gradually, up to 21 months following its original onset.

Conclusion
The potential for first-bite syndrome should be included in the preoperative discussion for those undergoing surgery of the parotid gland, neck, and/or parapharyngeal space. Patients who undergo external carotid artery ligation as part of these surgeries or who develop Horner’s syndrome postoperatively appear to be at highest risk for development of firstbite syndrome. Additional reports on the efficacy of botulinum toxin in alleviating the pain associated with firstbite syndrome are eagerly awaited.

Disclosures
The authors have no conflicts of interest to disclose. Funding was provided by the University of South Carolina and the South Carolina Center of Economic Excellence Center for Medication Safety initiative (C.L.B.).


References
1. Casserly P, Kiely P, Fenton JE. Cervical sympathetic chain schwannoma masquerading as a carotid body tumour with a postoperative complication of first-bite syndrome. Eur Arch Otorhinolaryngol 2009;266:1659–1662.

2. Netterville JL, Jackson CG, Miller FR, Wanamaker JR, Glasscock ME. Vagal paraganglioma: a review of 46 patients treated during a 20-year period. Arch Otolaryngol Head Neck Surg 1998;124:1133–1140.

3. Haubrich WS. The first-bite syndrome. Henry Ford Hosp Med J 1986;34:275–278.

4. Kawashima Y, Sumi T, Sugimoto T, Kishimoto S. First-bite syndrome: a review of 29 patients with parapharyngeal space tumor. Auris Nasus Larynx 2008;35:109–113.

5. Ali MJ, Orloff LA, Lustig LR, Eisele DW. Botulinum toxin in the treatment of first bite syndrome. Otolaryngol Head Neck Surg 2008;139:742–743.

6. Mandel L, Syrop SB. First-bite syndrome after parapharyngeal surgery for cervical schwannoma. J Am Dent Assoc 2008;139:1480– 1483.

7. Albasri H, Eley KA, Saeed NR. Chronic pain related to first bite syndrome: report of two cases. Br J Oral Maxillofac Surg 2011;49:154–156.

8. Chiu AG, Cohen JI, Burningham AR, Andersen PE, Davidson BJ. First bite syndrome: a complication of surgery involving the parapharyngeal space. Head Neck 2002;24:996–999.

9. Phillips TJ, Farquhar-Smith WP. Pharmacological treatment of a patient with firstbite syndrome. Anaesthesia 2009;64:97–98.

Pages

Recommended Reading

FDA Approves First Drug for Medullary Thyroid Cancer
MDedge Hematology and Oncology
BRAF Mutation Status May Change Papillary Thyroid Cancer Management
MDedge Hematology and Oncology
Smoking Cessation Can Reduce Late Side Effects of Radiotherapy
MDedge Hematology and Oncology
Two Factors Predict Postradiotherapy Swallowing Difficulties
MDedge Hematology and Oncology
Low EGFR Expression Predicts ARCON Benefit in Laryngeal Cancer
MDedge Hematology and Oncology
Larynx Preservation Studies Should Consider Treatment Impact
MDedge Hematology and Oncology
Feasibility and acceptance of a telehealth intervention to promote symptom management during treatment for head and neck cancer
MDedge Hematology and Oncology
Head & Neck Cancers
MDedge Hematology and Oncology
HPV-Related Oral Cancer Incidence Spikes Sharply
MDedge Hematology and Oncology
HPV-Related Oral Cancer Incidence Spikes Sharply
MDedge Hematology and Oncology